Sun Pharma's Halol facility issued eight observations by U.S. FDA

Sun Pharmaceutical Industries' drug manufacturing facility in Halol, Gujarat, has been issued eight observations by the U.S. Food and Drug Administration (FDA).
The U.S. FDA issued a Form-483 with eight observations following conclusion of a Good Manufacturing Practices (GMP) inspection of the facility from June 2-13, Sun Pharma said in a filing to the stock exchanges on Saturday.
'This is further to our update on Halol dated 16 December 2022,' the company said, referring to the warning letter the U.S. FDA had issued to the facility. The warning letter came close on the heels of regulator placing the Halol facility under import alert.
The warning letter had summarised violations with respect to current good manufacturing practice (cGMP) regulations.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Hindu

14 hours ago

• The Hindu

Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner

Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.

Business Standard

a day ago

• Business Standard

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

Natco Pharma announced that its pharmaceutical manufacturing facility in Kothur, Hyderabad, has received seven observations from the United States Food and Drug Administration (USFDA) following a recent inspection. In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 June to 19 June 2025. At the conclusion of inspection, the USFDA has issued a Form 483 with seven observations. Natco Pharma expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to current Good Manufacturing Practices (cGMP) and the consistent supply of high-quality pharmaceutical products to global markets. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The counter shed 0.98% to Rs 872.75 on the BSE.

Time of India

a day ago

• Time of India

HDB Financial's Rs 12,500 crore IPO: 10 key facts investors should know before June 25

Investor interest is building around the upcoming initial public offering of HDB Financial Services , the non-banking finance arm backed by HDFC Bank . At Rs 12,500 crore, the long-awaited issue is poised to be the largest of 2025 so far, drawing attention from both institutional players and retail participants. As the subscription window nears, here are 10 key facts investors should know. 1. GMP points to strong debut As of June 20, the grey market premium for HDB Financial stood at Rs 83, implying a listing price of Rs 823, an 11.22% premium to the issue's upper band. Market watchers note the GMP trend has been upward in recent sessions, signalling expectations of a firm listing. 2. The largest IPO of the year to date With a total issue size of Rs 12,500 crore, HDB Financial's IPO is set to be the biggest in 2025 so far. It also ranks as the largest public offering since Hyundai Motor India's Rs 27,000 crore IPO last year. 3. HDB Financial Services IPO price band The price band for the issue has been fixed at Rs 700 to Rs 740 per share. Investors are advised to consider bidding at the cut-off to improve allocation chances in the event of oversubscription. 4. Subscription window The IPO will open for subscription on Tuesday, June 25, and close on Thursday, June 27. The basis of allotment is expected to be finalised on Monday, June 30. 5. Tentative listing Shares of HDB Financial are expected to list on both the BSE and NSE on Wednesday, July 2, subject to final regulatory approvals. 6. Offer structure The IPO comprises a fresh issue of Rs 2,500 crore and an offer for sale worth Rs 10,000 crore by HDFC Bank, which currently holds a 94.6% stake in the company. The share sale forms part of the bank's broader capital optimisation strategy. 7. Quotas reserved The issue includes reserved portions for eligible employees of HDB Financial as well as shareholders of parent HDFC Bank . 8. Application sizes and investment requirements Retail investors can apply for a minimum of 20 shares, amounting to Rs 14,000 at the lower band and Rs 14,800 at the upper band. For small non-institutional investors applicants, the minimum investment is Rs 2,07,200 (14 lots); for big non-institutional investors, it is Rs 10,06,400 (68 lots). 9. Managed by a consortium of global and domestic banks The IPO is being led by a 13-member syndicate of book-running lead managers, including BofA Securities India, Goldman Sachs (India), Morgan Stanley, JM Financial , Motilal Oswal, and others. MUFG Intime India (Link Intime) is the registrar. 10. Key player in India's NBFC sector HDB Financial Services operates across retail and commercial lending segments, offering products such as personal loans, vehicle loans, gold loans, and loans against property. The company has a wide presence in semi-urban and rural markets, and intends to use the fresh issue proceeds to bolster capital adequacy and support lending growth. Also read | HDFC Bank shares in focus as Rs 12,500-crore HDB Financial IPO opens next week ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)